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Our objective was to assess the clinical factors that would
reliably distinguish methicillin-resistant S. aureus (MRSA)
from methicillin-susceptible S. aureus (MSSA) endocarditis. A
retrospective cohort study of clinical features and mortality in
patients with MRSA and MSSA endocarditis between March
1986 and March 2004 was performed in a 750-bed, tertiary
care teaching hospital. A total of 32 patients (10 MRSA
[31.3%] vs 22 MSSA [68.7%]) were evaluated. Their mean
age and sex ratio (male/female) were as follows: 30.8 ± 16.0
vs 24.4±19.6 years old and 6/4 vs 13/9, for MRSA and MSSA
infective endocarditis (IE), respectively. Univariate and multi-
variate analyses revealed that persistent bacteremia was sig-
nificantly more prevalent in MRSA IE (OR, 10.0 [1.480-
67.552]; p, 0.018). There was a higher mortality trend for
MRSA IE (50.0%) than for MSSA IE (9.1%) (p=0.019).
However, persistent bacteremia was not associated with higher
mortality (p>0.05). These results indicate that if persistent
bacteremia is documented, the likelihood of MRSA endo-
carditis should be viewed as high, and the patient's anti-
staphylococcal therapy should be prolonged and/or changed to
a more "potent" regimen.
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INTRODUCTION
Infective endocarditis (IE) is a serious septic dis-
ease that can be life-threatening, unless effective
therapy is initiated under the correct diagnosis. Al-
though there have been many developments and im-
provements in diagnostic and therapeutic methods,
the clinical diagnosis of infective endocarditis re-
mains sometimes difficult and the annual incidence,
morbidity, and mortality are still relatively high.1,2
Among IE-causing pathogens, S. aureus endo-
carditis has a higher mortality than endocarditis
caused by most other microorganisms.1,3-12 Overall
mortality associated with S. aureus bacteremia
ranges from 11.9%13 to 46.5%.14 Age, co-morbidity,
shock, inappropriate empirical therapy, bactere-
mia acquired in intensive care unit (ICU) and
severe sources of infection may be independent
predictors for mortality.15
Since the 1980s, the incidence of S. aureus bacte-
remia has increased due to the extensive use of
indwelling intravenous catheters.16,17 Predisposing
factors for methicillin-resistant S. aureus (MRSA)
infection include severe underlying conditions,
prolonged hospital stay, previous antibiotic treat-
ment, and nasal MRSA carriage.
16,18
Since nosocomial S. aureus bacteremias are in-
creasingly due to MRSA, it is important to iden-
tify clinical features of endocarditis that can help
distinguish between MRSA and MSSA infections.
Few data exist comparing the relative rates and
clinical characteristics of endocarditis due to
MRSA and MSSA.
The aim of this study was to assess clinical fac-
tors that would reliably distinguish between
MRSA and MSSA endocarditis in order to quickly
and properly manage MRSA IE.
MATERIALS AND METHODS
We performed a retrospective cohort study
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identifying clinical features and mortality in
patients with MRSA and MSSA endocarditis
between March 1986 and March 2004 at the
Yongdong Severance hospital in the Republic of
Korea. The facility was a 750-bed university-
affiliated tertiary care hospital. All patients with
at least 2 positive blood cultures for S. aureus and
who met the 1994 Duke criteria and modification19
were entered into a database.
Nosocomial endocarditis was defined as endo-
carditis acquired more than 3 days after the hos-
pital admission date with no clinical manifesta-
tions of endocarditis before admission. Persistent
bacteremia was defined as the presence of positive
blood cultures for S. aureus after 3 days of
empirical anti-staphylococcal antibiotic therapy.
Prior antibiotic use and start of antibiotic within
24 h were considered present when an antibiotic
was administered for > 48 h within 2 weeks prior
to the first positive blood culture and when an
antibiotic was started within 24 h of the onset of
symptoms.
Microbiological and antimicrobial susceptibility
results were obtained from the clinical micro-
biology database. S. aureus isolates were identified
by the growth of coagulase- and catalase-positive
gram-positive cocci. Methicillin resistance was
determined by the lack of inhibition of growth by
an oxacillin disc on mannitol salt agar, according
to the criteria of the National Committee for
Clinical Laboratory Standards.20
Each patient's hospital chart was retrospectively
reviewed. The factors assessed included the
patients' demographics, the duration of fever, the
origin of infection (unknown, skin, CSF, dental,
bone, joint, urinary), whether there was a com-
munity or nosocomial source of infection, the
presence of heart disease (native or prosthetic
valve, prior endocarditis, congenital heart disease,
rheumatic heart disease, pacemaker implantation),
co-morbidity (diabetes mellitus, liver cirrhosis,
neurologic disease, pregnancy, trauma, burn, acute
renal failure [ARF]), vegetation (right/left), shock,
secondary metastatic infection, atrioventricular
[AV] block, prior antibiotic use, start of antibiotic
within 24 h, mechanical ventilation, and cardiac
operation, laboratory findings (white blood cell
count [WBC], creatinine, persistent bacteremia [
3 days]), and mortality.
Univariate analyses using a 2 test or an inde-
pendent t test were carried out to determine the
risk factors for MRSA IE. Multivariate analysis
was performed to assess the independence of the
statistically significant variables in univariate
analysis, using a multiple logistic regression
model. A p value < 0.05 was considered signifi-
cant. The SPSS version 11.0 statistical software
package for Windows was used for all statistical
analyses.
RESULTS
A total of 32 patients met the aforementioned
criteria and were included in this study. Of these
patients, 10 (31.3%) had MRSA bacteremia and 22
(68.7%) had MSSA bacteremia. Their mean age
and sex ratio (male/female) are as follows: 30.8 ±
16.0 vs 24.4 ± 19.6 years old and 13/9 vs 6/4 for
MRSA and MSSA infections, respectively. Other
demographic and clinical characteristics for these
MRSA- and MSSA-infected patients are shown in
Table 1.
Compared with the MSSA-infected patients,
those with MRSA IE had more infections of skin
origin (cellulitis), an increased presence of co-
morbidity, right sided vegetation, nosocomial in-
fection, persistent bacteremia, mechanical ventila-
tion, prior antibiotic use, and a higher rate of
mortality (p < 0.05). MSSA-infected patients were
more likely to have begun antibiotics within 24 h
of the onset of symptoms and to have an un-
known site of origin for the infection (p < 0.05). No
statistically significant differences were noted for
age, sex, the duration of fever, the presence of
heart disease (native or prosthetic valve, prior
endocarditis, congenital heart disease, rheumatic
heart disease, pacemaker implantation), shock,
secondary metastatic infection, AV block, and
cardiac operation, and laboratory findings (WBC,
creatinine).
Factors demonstrating an association with
MRSA endocarditis by univariate analyses were
evaluated in a multiple logistic regression model.
Statistically significant associations were found
only with the presence of persistent bacteremia
(odds ratio [OR], 10.0; 95% confidence intervals
[CI], 1.480-67.552; p, 0.018). There was a trend of
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higher mortality for MRSA IE (50.0%) than for
MSSA IE (9.1%) (p=0.019). However, persistent
bacteremia itself was not associated with higher
mortality (p > 0.05).
We used a univariate analysis to analyze the
effects of an empirical antibiotic regimen (Table 2)
on persistent bacteremia. The use of vancomycin
was associated with persistent bacteremia, but this
association was not significant (p=0.075).
Table 1. Descriptive Characteristics and Univariate Analysis of Patients in a Study of Methicillin-Resistant vs Methicillin-
Sensitive S. aureus Infectious Endocarditis (IE)
Variables
Patients with MRSA IE
(N=10)
Patients with MSSA IE
(N=22)
p-value
Age (yrs) 30.8 ± 16.0 24.4 ± 19.6 NS
Sex (M/F) 6/4 13/9 NS
Co-morbidity (%)
Diabetes mellitus
Liver cirrhosis
Neurologic disease
Pregnancy
Trauma
Burn
Acute renal failure
8 (80.0)
1 (10.0)
1 (10.0)
1 (10.0)
2 (20.0)
2 (20.0)
2 (20.0)
2 (9.1)
2 (9.1)
<0.001
NS
NS
NS
NS
NS
NS
NS
Heart disease (%)
Native valve
Prosthetic valve
Prior endocarditis
Congenital heart disease
Rheumatic heart disease
Pacemaker implantation
3 (30.0)
7 (70.0)
1 (10.0)
2 (20.0)
14 (63.6)
8 (36.4)
3 (13.6)
1 (4.5)
9 (40.9)
1 (4.5)
1 (4.5)
NS
NS
NS
NS
NS
NS
NS
Origin (%)
Unknown
Skin
Others (CSF, dental, bone, joint, urinary)
1 (10.0)
7 (70.0)
2 (20.0)
18 (81.8)
1 (4.5)
3 (13.6)
<0.001
<0.001
NS
Vegetation (%)
Right sided
10 (100.0)
7 (70.0)
17 (77.3)
3 (13.6)
NS
0.001
Duration of fever, days 7.3 ± 4.5 9.6 ± 8.9 NS
Shock (%) 4 (40.0) 6 (27.3) NS
Nosocomial infection (%) 6 (60.0) 7 (31.8) <0.001
Secondary metastatic infection (%) 4 (40.0) 8 (36.4) NS
Atrioventricular block (%) 1 (10.0) 3 (13.6) NS
Prior antibiotic use (%)
Start of antibiotic within 24 h (%)
7 (70.0)
4 (40.0)
5 (22.7)
18 (81.8)
0.018
0.037
Mechanical ventilation (%) 4 (40.0) 2 (9.1) 0.038
Cardiac operation (%) 5 (50.0) 4 (18.2) NS
Laboratory findings
Creatinine (mg/dL)
White blood cell count (/ L)μ
Persistent bacteremia (%)
0.8 ± 0.3
16,125 ± 6,776
5 (50.0)
1.0 ± 0.5
13,808 ± 8,124
2 (9.1)
NS
NS
0.019
Mortality (%) 5 (50.0) 2 (9.1) 0.019
MRSA, methicillin-resistant S. aureus; MSSA, methicillin-susceptible S. aureus; NS, statistically not significant (p > 0.05).
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DISCUSSION
MRSA endocarditis represented only 3% (16/
559) of S. aureus infections in 9 large series of
retrospective reviews of endocarditis reported
before 1998.10,21-26 In a recent review of endocar-
ditis cases at Duke University Medical Center
from 1993 to 1999, S. aureus was the etiologic
agent in 16% of Staphylococcal endocarditis cases,
with most cases occurring in the last 3 years of the
study.27 In a survey of infective endocarditis in
Japan during 2000 and 2001,28 MRSA was found
in 23.1% of cases. In the present study, MRSA was
the cause of 31% (10/32) of staphylococcal
endocarditis, similar to data recently reported by
Chang et al.29 These results reveal a current trend
of increasing MRSA IE.
Despite continuous efforts to control MRSA
transmission in the hospital, MRSA infection
remains a major worldwide concern, and the true
impact of MRSA infection on morbidity and
mortality remains highly controversial. Although
a plethora of clinical studies have demonstrated
the virulence of MRSA strains, it has been shown
that many MRSA strains neither are highly
contagious nor possess virulence determinants.
30
MRSA strains did not differ from MSSA strains in
intra-leukocyte survival or phagocytic destruction,
animal lethality studies, or in the production of
extra-cellular hemolysins, enzymes, or toxins.31,32
In addition, Hong Kong strains of MRSA and
MSSA were found to be equally pathogenic.33
Although some studies,13,18,29,33-42 including a
recent meta-analysis of S. aureus bacteremia,43
have found higher mortality rates among patients
with MRSA infection than among those infected
with MSSA, many studies failed to identify a rela-
tionship between MRSA and mortality.14,15,33,44-53
Our study revealed a trend of higher mortality in
MRSA IE (50.0%) than in MSSA IE (9.1%) (p=
0.019, Table 1). This finding may be due to the
increased presence of co-morbidity (80.0% vs.
9.1%) and a nosocomial origin of infection (60.0%
vs. 31.8%) in MRSA IE patients, which is consis-
tent with previous findings.15 However, within
this interpretation, it is important to consider
several confounding factors, including the end
points chosen (crude vs. infection-related mor-
tality), major differences in patient populations,
preexisting co-morbidities, the severity of S. aureus
infection at the time of diagnosis, sites of infec-
tion, and high rates of inappropriate empirical
antibiotic regimens prescribed for treatment of
MRSA infections.14-16,18,33-40,43-52 Accordingly, more
sophisticated clinical studies are required to ad-
dress these concerns.
Generally, MRSA infections are reportedly more
frequent after a longer duration of hospitaliza-
tion,18,33,41 or concomitant with severe underlying
disease,
33,41,54,55
intra-vascular catheter infection,
41,55
wound infection,41 hospitalization in an ICU,55 and
after prior antibiotic treatment.33,41,48,55,56 One of the
major confounders in studying MRSA and MSSA
pathogenicity might be the higher rates of inap-
propriate empirical antimicrobial treatments pre-
scribed to MRSA-infected patients, which ranged
from 8% to 55% in previous studies.15,37,44,46 One
retrospective review showed that 75% (6/8) of
patients experiencing recurrent S. aureus bactere-
mia had received prior vancomycin therapy.57
Although not significant in our studies, there was
a trend toward higher rates of prior antibiotic use
in MRSA infection (70.0% vs. 22.7%). So, it can be
assumed that unnecessary use of antibiotics
should be avoided.
In a comparison between MRSA and MSSA
Table 2. Empirical Antibiotic Regimens Used in This Study
Antibiotics
Patients with MRSA IE
(N=10)
Patients with MSSA IE
(N=22)
Vancomycin (%)
Teicoplanin (%)
Arbekacin (%)
Ampicillin/sulbactam (%)
1st generation cephalosporins (%)
7 (70.0)
2 (20.0)
1 (10.0)
-
-
9 (40.9)
3 (13.6)
-
7 (31.8)
3 (13.7)
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endocarditis, Abraham reported that community-
acquired MSSA bacteremia was the cause of most
of the community-acquired S. aureus endocarditis
and the nosocomially acquired MRSA bacteremia
was the cause of most of the nosocomially
acquired S. aureus endocarditis.55 Our results also
showed that MRSA endocarditis was more likely
to be hospital-acquired (p=0.001, Table 1). In
addition, we found that right-sided vegetations
were associated with both MRSA IE (p=0.001) and
nosocomial infection (p=0.038).
Chang et al. reported that patients with endo-
carditis due to MRSA were significantly more
likely to experience persistent bacteremia than
those with endocarditis due to MSSA.29 In our
study, persistent bacteremia also occurred signifi-
cantly more frequently in endocarditis caused by
MRSA than by MSSA. In endocarditis, the
organisms within vegetations are presumed to be
in the lag phase of growth. Hence, it is possible
that the delayed response to vancomycin therapy
reflects the slow killing by vancomycin of
organisms in this lag phase of growth.58 Our study
revealed that the use of vancomycin was asso-
ciated with persistent bacteremia, although not
significantly (p=0.075). Thus, it can be reasoned
that persistent bacteremia may be one of predic-
tors of MRSA infective endocarditis, with less
significant effect of the slow response of vanco-
mycin. Additionally, Lesens et al. reported that
sustained bacteremia was significantly associated
with a higher frequency of secondary metastatic
infection and with a higher frequency of CRP >
100 mg/L.
57
However, our results did not show
such associations.
Emergence of MRSA as a common pathogen
has added new challenges to the management of
IE. Vancomycin is the most appropriate antibiotic
choice for the treatment of MRSA IE. For the
vancomycin-intolerant patient, antibiotic choices
should be made on the basis of antimicrobial sus-
ceptibilities and the severity of infection. MRSA is
also susceptible to quinupristin-dalfopristin and
linezolid. Rifampin combinations might be con-
sidered in situations such as prosthetic valve
endocarditis. Moreover, in one study, a combi-
nation of rifampin and ciprofloxacin cured 100%
(10/10) of intravenous drug abusers with right-
sided S. aureus endocarditis.59 It is practical to use
these drugs in combination to prevent the
emergence of quinolone resistance during therapy
for an S. aureus infection, provided the MRSA
strain is susceptible to both fluoroquinolone and
rifampin.60 It seems reasonable to add gentamicin
for the first 3 to 5 days of therapy to promote a
more rapid clearing of bacteremia and mini-
mization of damage to the heart valve, while
avoiding the toxic reactions associated with more
prolonged courses of aminoglycosides.61
The findings of our study are particularly
important because of the increasing incidence of
S. aureus bacteremia and the recent increase in
frequency of nosocomial S. aureus bacteremia that
has resulted in an increased incidence of IE. If
persistent bacteremia is documented, the likeli-
hood of MRSA endocarditis should be viewed as
high, and as a result, empiric treatment with
antibiotics active against MRSA would be jus-
tified. In addition, consideration should be given
to "optimizing" the patient's antimicrobial regi-
men (by using either a more "potent" therapy or
a combination antibiotic therapy), prolonging the
duration of therapy, and/or exploring the advisa-
bility of early surgical intervention. In conclusion,
our study affirms the importance of persistent
bacteremia as a predictor of MRSA infection.
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